Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIC: LP-300 + carboplatin + pemetrexed in never-smoker relapsed NSCLC (adenocarcinoma) after TKIs
jRCT2061240024Phase 2Recruiting
- Sponsor
- Lantern Pharma
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 2, single-arm trial of dimesna in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC), sponsored by Lantern Pharma. Primary endpoints: Progression-free survival and Overall survival. Started Nov 2024; status: recruiting.
02
Drugs
dimesna
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061240024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240024.